Lutetium Lu 177 Dotatate Patent Expiration
Lutetium Lu 177 Dotatate was first introduced by Advanced Accelerator Applications Usa Inc
Lutetium Lu 177 Dotatate Patents
Given below is the list of patents protecting Lutetium Lu 177 Dotatate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lutathera |
US10596276 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US10596278 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US11904027 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12144873 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12151003 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12161732 (Pediatric) | Stable, concentrated radionuclide complex solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12168063 (Pediatric) | Stable, Concentrated Radionuclide Complex Solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12415003 (Pediatric) | Stable, Concentrated Radionuclide Complex Solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera |
US12491272 (Pediatric) | Stable, Concentrated Radionuclide Complex Solutions | Jan 25, 2039 | Aaa Usa Inc |
| Lutathera | US10596276 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US10596278 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US11904027 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12144873 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12151003 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12161732 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12168063 | Stable, concentrated radionuclide complex solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12415003 | Stable, Concentrated Radionuclide Complex Solutions | Jul 25, 2038 | Aaa Usa Inc |
| Lutathera | US12491272 | Stable, Concentrated Radionuclide Complex Solutions | Jul 25, 2038 | Aaa Usa Inc |
Lutetium Lu 177 Dotatate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lutetium Lu 177 Dotatate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
